trial · primary record
Placebo Matching Mitapivat
Transfusion-dependent Alpha-Thalassemia
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 258 |
| Primary completion | 2029-06 |
| Primary endpoint | Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) |
| Registry ID | NCT04770779 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:59.655Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04770779
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.